Sector portfolio · VC firm · France
Omnes' Biotech portfolio
Omnes has backed 12 Biotech startups in rounds we track, $669M between them, shown by the stage each has reached. The best-funded is Biovex.
Funding by segment
- Series A$169M5
- Stage not reported$124M4
- Series C and later$376M3
Where they are based
- France7$357M
- Austria1$56M
- Italy1$9.2M
- United Kingdom1$133M
- Belgium1$112M
France
Austria
Italy
United Kingdom
BelgiumFounded
2 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M2
- $10M to $50M4
- $50M to $250M6
- $250M to $1B0
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
10 of 12 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- France7
- Austria1
- Italy1
- United Kingdom1
- Belgium1
Startups by country, 5 countries in all.
Segment by segment
Series A
5 startups · $169M raised
Corteria PharmaceuticalsCorteria Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2021.France$70M
DiogenXDiogenX is a preclinical-stage biotechnology company founded in 2020, based in Marseille, France, with research laboratories in Nice.France$37M
Coave TherapeuticsHorama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.France$33M- NTNH TherAguixNH TherAguix is a clinical stage company.France$15M
AntabioANTABIO is a clinical-stage biopharmaceutical company based in Labege, France, focused on developing innovative antibacterial therapies.France$15M
Stage not reported
4 startups · $124M raised
ENTEROMEEnterome SA is a clinical-stage biopharmaceutical company based in Paris, France, with operations in Évry.France$58M- TThemisAustria$56M
NewronikaNewronika restores brain and body functions with innovative technologies.Italy$9.2M
OCTIMET OncologyOCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles-$1.3M
Series C and later
3 startups · $376M raised
- BBioVexTHOUSAND OAKS, Calif., March 4, 2011 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN), today announced the completion of the acquisUnited Kingdom$133M
- TTISSIUMFrance$131M
AgomAB TherapeuticsAgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.Belgium$112M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Omnes as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like Omnes?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.